Bicyclic heterocyclyl derivatives as irak4 inhibitors

A method of treating an IRAK4-mediated disorder, disease, or condition in a subject, comprising administering a compound of formula (I):

• or a pharmaceutically acceptable salt or a stereoisomer thereof;
• wherein
• X1 and X3 independently are CH or N;
• X2 is CR2 or N;
• provided one and not more than one of X1, X2 or X3 is N;
• A is O or S;
• Y is —CH2— or O;
• Z is aryl or heterocyclyl;
• R1, at each occurrence, is independently halo or optionally substituted heterocyclyl;
• wherein the substituent is alkyl, alkoxy, aminoalkyl, halo, hydroxyl, hydroxyalkyl or —NRaRb;
• R2 is hydrogen, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl or —NRaRb;
• wherein the substituent is alkyl, amino, halo or hydroxyl;
• R3, at each occurrence, is alkyl or hydroxyl;
• Ra and Rb are independently hydrogen, alkyl, acyl or heterocyclyl;
• ‘m’ and ‘n’ are independently 0, 1 or 2;
• ‘p’ is 0 or 1.